UBS Maintains a 'Neutral' on Complete Genomic (GNOM); Deal Visibility Still Low
Tweet
Share
E-mailGet Alerts GNOM Hot Sheet
Price: $58.31 --0%
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Rating Summary:
1 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Join SI Premium – FREE
UBS maintains a 'Neutral' on Complete Genomic (NASDAQ: GNOM) price target raised $1 to $4.
UBS analyst says, "GNOM reported Q4 sales of $2.5M (-35% y/y; -41% q/q), just below UBSe $2.7M and Street $3.2M. The shipment of 600 genomes was in-line with pre-announced levels, and implies an ASP per genome of $4,200. Adj loss per share of $0.67 was below Street ($0.64) & UBSe ($0.52) due to higher R&D of $8M (UBSe $7M) and SG&A of $8.3M (UBSe $5M)."
"In our view, the stock now hangs on the ability to complete a big deal, and we expect volatility to remain high going forward. While we believe a large order will be booked in ’12, our model assumes such (our $34M rev forecast implies ~10k genomes), and visibility on timing is low. This, along with the risk associated with a rapidly changing competitive landscape and GNOM’s need to raise cash, keep us Neutral on shares." (UBS lowers FY12 EPS loss from (1.71) to (2.16) and FY13 from (1.29) to (1.70))
For an analyst ratings summary and ratings history on Complete Genomic click here. For more ratings news on Complete Genomic click here.
Shares of Complete Genomic closed at $3.83 yesterday.
UBS analyst says, "GNOM reported Q4 sales of $2.5M (-35% y/y; -41% q/q), just below UBSe $2.7M and Street $3.2M. The shipment of 600 genomes was in-line with pre-announced levels, and implies an ASP per genome of $4,200. Adj loss per share of $0.67 was below Street ($0.64) & UBSe ($0.52) due to higher R&D of $8M (UBSe $7M) and SG&A of $8.3M (UBSe $5M)."
"In our view, the stock now hangs on the ability to complete a big deal, and we expect volatility to remain high going forward. While we believe a large order will be booked in ’12, our model assumes such (our $34M rev forecast implies ~10k genomes), and visibility on timing is low. This, along with the risk associated with a rapidly changing competitive landscape and GNOM’s need to raise cash, keep us Neutral on shares." (UBS lowers FY12 EPS loss from (1.71) to (2.16) and FY13 from (1.29) to (1.70))
For an analyst ratings summary and ratings history on Complete Genomic click here. For more ratings news on Complete Genomic click here.
Shares of Complete Genomic closed at $3.83 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $135 at Guggenheim
- Wedbush Starts Immunic Inc. (IMUX) at Outperform
- Home Depot (HD) PT Raised to $340 at Stifel Amid 'Sea Change in Investor Sentiment'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
